Analysis of Survival Modification by Furosemide Use in a Cohort of Hospitalized COVID-19 Patients with Severe or Critical Disease in Mexico: Due to Its Chemical Structure, Furosemide Is More than Just a Diuretic

Author:

Diaz-Martinez Janet1ORCID,Kotzker Wayne2,Mendoza-Hernandez Martha A.34ORCID,Gadh Rajdeep S.5,Hernandez-Fuentes Gustavo A.3ORCID,Bañuelos Andrew6,Guzmán-Esquivel José7ORCID,Hong Angelina6,Delgado-Enciso Osiris G.3,Geyer-Roberts Elizabeth8,Martinez-Fierro Margarita L.9ORCID,Rodriguez-Sanchez Iram P.10ORCID,Garza-Veloz Idalia9,Canseco-Ávila Luis M.11ORCID,Delgado-Enciso Ivan31213ORCID

Affiliation:

1. Research Center in Minority Institutions, Robert Stempel College of Public Health, Florida International University, Miami, FL 33199, USA

2. Florida Kidney Physicians, Panoramic Health Practice, Boca Raton, FL 33431, USA

3. Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico

4. COVID Unit, General Hospital Number 1, Mexican Institute of Social Security, Villa de Alvarez, Colima 29883, Mexico

5. Florida Kidney Physicians, Panoramic Health Practice, Coral Springs, FL 33071, USA

6. Department GME (General Medicine Education), Hospital Corporation of America Westside, Westside, FL 33324, USA

7. Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Colima 29883, Mexico

8. Department of Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova University, Fort Lauderdale, FL 33328, USA

9. Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico

10. Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolas de los Garza 66455, Mexico

11. Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula 30700, Mexico

12. Department of Research, Colima Cancerology State Institute, Mexican Institute of Social Security (IMSS-Bienestar) Colima, Colima 28085, Mexico

13. Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA

Abstract

In the ongoing fight against Coronavirus Disease 2019 (COVID-19), researchers are exploring potential treatments to improve outcomes, especially in severe cases. This includes investigating the repurposing of existing medications, such as furosemide, which is widely available. This study aimed to evaluate the impact of furosemide on mortality rates among COVID-19 patients with severe or critical illness. We assessed a cohort of 515 hospitalized adults who experienced a high mortality rate of 43.9%. Using a multivariate analysis with adjusted risk ratios (AdRRs), factors like smoking (AdRR 2.48, 95% CI 1.53–4.01, p < 0.001), a high Pneumonia Severity Index (PSI) score (AdRR 7.89, 95% CI 5.82–10.70, p < 0.001), mechanical ventilation (AdRR 23.12, 95% CI 17.28–30.92, p < 0.001), neutrophilia (AdRR 2.12, 95% CI 1.52–2.95, p < 0.001), and an elevated neutrophil-to-lymphocyte ratio (NLR) (AdRR 2.39, 95% CI 1.72–3.32, p < 0.001) were found to increase mortality risk. In contrast, vaccination and furosemide use were associated with reduced mortality risk (AdRR 0.58, p = 0.001 and 0.60, p = 0.008; respectively). Furosemide showed a pronounced survival benefit in patients with less severe disease (PSI < 120) and those not on hemodialysis, with mortality rates significantly lower in furosemide users (3.7% vs. 25.7%). A Kaplan–Meier analysis confirmed longer survival and better oxygenation levels in patients treated with furosemide. Furthermore, a Structure–Activity Relationship analysis revealed that furosemide’s sulfonamide groups may interact with cytokine sites such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), potentially explaining its beneficial effects in COVID-19 management. These findings suggest that furosemide could be a beneficial treatment option in certain COVID-19 patient groups, enhancing survival and improving oxygenation.

Funder

National Council of Humanities, Sciences and Technologies

Publisher

MDPI AG

Reference72 articles.

1. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China;Huang;Lancet,2020

2. World Health Organization (WHO) (2024, April 28). World Health Organization 2023 Data. Who.Int, WHO Coronavirus (COVID-19) Dashboard > about [Dashboard]. Available online: https://data.who.int/dashboards/covid19/about.

3. CONACYT (Consejo Nacional de Ciencia y Tecnología), CentroGeo (Centro de Investigación en Ciencias de Información Geoespacial), and GeoInt (Laboratorio Nacional de GeoInteligencia) (2023, March 19). DataLab COVID-19 Tablero México. Available online: https://datos.covid-19.conacyt.mx/.

4. Potential Therapeutic Options for COVID-19: An Update on Current Evidence;Niknam;Eur. J. Med. Res.,2022

5. Lessons Learned from Health Disparities in Coronavirus Disease-2019 in the United States;Diaz;Clin. Chest Med.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3